Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Q4 2022 Earnings Presentation
13 slides from Hansa Biopharma Ab's earnings presentation, Feb 2, 2023
Slide 1: Conference Call Presentation: Year-end Report Jan-Dec 2022
Conference Call Presentation Year-end Report Jan-Dec 2022 Lund, February 2, 2023
Slide 2: Forward-looking statements
Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occ
Slide 3: Total 2022 revenue of SEK 155m; cash runway extended into 2025
Total 2022 revenue of SEK 155m; Cash runway extended into 2025; Market Access secured in Italy and Czech Republic; Reported positive Phase 2 top-line data in AMR Highlights for the fourth quarter of 2022 ü Idefirix launch in Europe is progressing as planned - Total Q4 revenue of SEK 31m including SE
Slide 4: Positive reimbursement decisions received in four of the five largest markets
Positive reimbursement decisions received in four of the five largest markets including Italy, U.K., Germany and France (early access) Market access has now been secured in 11 European countries and procedures are ongoing in nine countries including Spain as the last of the five major European marke
Slide 5: Continuous progress in our ongoing clinical programs
Continuous progress in our ongoing clinical programs Enrollment status Enrollment status Feb 1, 2023 Feb 1, 2023 Antibody Mediated Rejection Phase 2 study Anti-GBM Phase 3 study • 30/30 patients enrolled in the AMR phase 2 study • New pivotal Phase 3 study initiated in first sites in the U.S. and •
Slide 6: Broad clinical pipeline in transplantation and auto-immune diseases
Broad clinical pipeline in transplantation and auto-immune diseases Potentially Candidate/ Research/ Pivotal/ Marketing Project Indication Preclinical Phase 1 Phase 2 Phase 3 Authorization Marketed Next Anticipated Milestone EU: Additional agreements around EU: Kidney transplantation in highly sensi
Slide 7: Total 2022 revenue of SEK 155m; Q4 2022 revenue SEK 31m
Total 2022 revenue of SEK 155m; Q4 2022 Revenue amounted to SEK 31m including SEK 20m in product sales Revenue (Q/Q) Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 67,1 22.7 30,3 30,8 SEKm 26,4 Product sales 15,4 43.7 24.2 20.3 19.5 Revenue recognition from 9.0 9.2 5.3 5.2 6.2 AskBio and Sarepta 1.1 0.8 0.8 0.7 1.3
Slide 8: For 2022 SG&A amounted to SEK 336m, R&D costs SEK 346m
For 2022 SG&A amounted to SEK 336m, while R&D costs amounted to SEK 346m, as Hansa continues to invest in commercial and pipeline activities SG&A expenses (Q/Q) R&D expenses (Q/Q) Net loss (Q/Q) Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 -103 -80 -90 -8
Slide 9: Cash runway now extends into 2025
Hansa’s cash runway now extends into 2025 as a result of a non-dilutive debt-financing of USD ~70m in July 2022 and an equity financing of USD ~40m in December 2022 Operating cash flow (Q/Q) Cash & short-term investments (Q/Q) Number of employees (Q/Q) Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 -116 -131 -129 -1
Slide 10: Near term milestones
Near term milestones Sarepta DMD U.S. Kidney GBS Phase 2 U.S. Kidney pre-treatment: AMR Phase 2: transplantation: complete transplantation: Commence Full data Complete enrollment Complete enrollment clinical study readout randomization (H1 2023) (H1 2023) (2023) (H2 2023) (H2 2023) 2023 2024 Anti-GB
Slide 11: Q&A
Q&A Visit our new web site www.hansabiopharma.com … at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives… 11 11
Slide 12: Contact our Investor Relations and Corporate Affairs team
Contact our Investor Relations and Corporate Affairs team Contact Calendar and events Feb 9, 2023 Mid-cap event, Frankfurt Klaus Sindahl Feb 23, 2023 Erik Penser Healthcare seminar, Stockholm VP, Head of Investor Relations Mar 7, 2023 Redeye Healthcare seminar: Commercialization, Stockholm Mobile: +
Slide 13: HANSAT
MZ HANSAT BIOPHARMA